NCT04764487View on ClinicalTrials.gov

A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

PHASE3UnknownINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

June 7, 2023

Study Completion Date

June 15, 2025

Conditions
Renal Cell Carcinoma Metastatic
Interventions
DEVICE

KidneyPRO

Web-application for symptoms assessment

OTHER

standard follow-up

usual follow-up

Trial Locations (13)

5100

RECRUITING

Institut Jean Godinot, Reims

14076

NOT_YET_RECRUITING

Centre François Baclesse, Caen

25000

NOT_YET_RECRUITING

CHU Jean Minjoz, Besançon

29000

RECRUITING

Clilnique Pasteur, Brest

29609

NOT_YET_RECRUITING

CHRU Brest, Brest

31059

NOT_YET_RECRUITING

Institut Claudius Regaud, Toulouse

35760

RECRUITING

CHP St Grégoire, Saint-Grégoire

37000

NOT_YET_RECRUITING

CHU Bretonneau, Tours

49055

NOT_YET_RECRUITING

Institut de Cancérologie de l'Ouest, Angers

67091

RECRUITING

Hôpitaux universitaires de Strasbourg, Strasbourg

69373

NOT_YET_RECRUITING

Centre Léon Bérard, Lyon

72000

RECRUITING

Clinique Victor Hugo / Centre Jean Bernard, Le Mans

85925

RECRUITING

CHD Vendée, La Roche-sur-Yon

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

FLGXPL

UNKNOWN

lead

Weprom

OTHER

NCT04764487 - A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line | Biotech Hunter | Biotech Hunter